Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy. Table 2. nano-siRNA therapeutic agents in clinical trials for the pancreatic cancer therapy.
Therapeutic siRNAs/interventions Targeted gene Delivery Diseased Condition Phase Status Sponsor Results/comments NCT number Ref.
siG12D-LODER/ Gemcitabine+nab-Paclitaxel KRAS-G12D Intratumor placement, Surgical implantation/ LODER polymer Pancreatic Cancer II Recruiting Silenseed Ltd siG12D-LODERTM consists of two major parts. The first part is a polymeric matrix which encapsulates the second part, anti-KRASG12D siRNA. This therapeutic agent shows prolonged antitumor effect, due to slow release. NCT01676259 (Golan et al., 2015; Weng et al., 2019)
siG12D LODER KRAS-G12D Intratumor placement, Surgical implantation/ LODER polymer Pancreatic Cancer I Completed Silenseed Ltd KRAS oncogene mutations (commonly G12D) has been mostly observed in the PDAC, as a result, stable KRASG12D siRNA drug treatment is promising strategy to cause apoptosis of such pancreatic tumor cells. NCT01188785 (Golan et al., 2015)
KRAS-G12D siRNA KRAS-G12D i.v. infusion/ Mesenchymal Stromal Cells-derived Exosomes Pancreatic Cancer I Not yet recruiting M.D. Anderson Cancer Center In these clinical trial studies, the most suitable dose and adverse effects of using exosomes derived from mesenchymal stromal cells for KrasG12D siRNA (iExosomes) delivery in treating participants with metastatic pancreatic cancer with KrasG12D mutation has been studied. iExosomes can show higher efficacy in pancreatic cancer therapy. NCT03608631 (Das, Musetti, & Huang, 2018; Elahi, Farwell, Nolta, & Anderson, 2019)
Atu027 & gemcitabine PKN3 i.v./ cationic lipoplex Metastatic Pancreatic Cancer I/II Completed Silence Therapeutics GmbH Atu027, which has great antimetastatic effect, is a siRNA-encapsulated liposome. This drug can suppress the expression of protein kinase N3 (PKN3) in the vascular endothelium. PKN3 is believed to be a Rho effector, which mediates the growth of pancreatic cancer cell downstream of PI3K. It has been shown that gemcitabine and Atu027 combination is safe for advanced pancreatic cancer therapy. NCT01808638 (Schultheis et al., 2018; Strumberg et al., 2012)
TKM-080301 PLK1 i.v./ LNP Pancreas Cancer with Hepatic Metastasis I Completed National Cancer Institute (NCI) TKM-080301 is a lipid nanoparticle siRNA delivery system. This therapeutic agent can efficiently suppress polo-like kinase 1 (PLK1) expression. It has been demonstrated that TKM-080301 has antitumor efficacy for pancreas cancer with hepatic metastases. NCT01437007 (Demeure et al., 2016)